Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Lindsley RC, Chen EC, Ramos Perez J, Stein A, DeAngelo DJ, Neuberg DS, Stone RM, Ball B, Stahl M. Shimony S, et al. Among authors: goldberg ad. Leukemia. 2024 Apr;38(4):762-768. doi: 10.1038/s41375-024-02175-0. Epub 2024 Feb 20. Leukemia. 2024. PMID: 38378841
Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.
Talati C, Goldberg AD, Przespolewski A, Chan O, Ali NA, Kim J, Famulare C, Sallman D, Padron E, Kuykendall A, Lancet JE, Wang E, Tallman MS, Komrokji R, Sweet K. Talati C, et al. Among authors: goldberg ad. Leuk Res. 2020 Jun;93:106367. doi: 10.1016/j.leukres.2020.106367. Epub 2020 May 1. Leuk Res. 2020. PMID: 32408060 Free PMC article.
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.
Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Zeidan AM, et al. Among authors: goldberg ad. Lancet Haematol. 2020 Aug;7(8):e601-e612. doi: 10.1016/S2352-3026(20)30205-2. Epub 2020 Jun 18. Lancet Haematol. 2020. PMID: 32563283 Free PMC article. Review.
Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure.
Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M, Gill SI, Manning BM, Koprivnikar J, McCloskey J, Testi R, Prebet T, Al Ali NH, Padron E, Sallman DA, Komrokji RS, Goldberg AD. Ball BJ, et al. Among authors: goldberg ad. Blood Adv. 2020 Jul 14;4(13):2866-2870. doi: 10.1182/bloodadvances.2020001482. Blood Adv. 2020. PMID: 32589727 Free PMC article.
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition.
Cai SF, Chu SH, Goldberg AD, Parvin S, Koche RP, Glass JL, Stein EM, Tallman MS, Sen F, Famulare CA, Cusan M, Huang CH, Chen CW, Zou L, Cordner KB, DelGaudio NL, Durani V, Kini M, Rex M, Tian HS, Zuber J, Baslan T, Lowe SW, Rienhoff HY Jr, Letai A, Levine RL, Armstrong SA. Cai SF, et al. Among authors: goldberg ad. Cancer Discov. 2020 Oct;10(10):1500-1513. doi: 10.1158/2159-8290.CD-19-1469. Epub 2020 Jun 30. Cancer Discov. 2020. PMID: 32606137 Free PMC article.
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.
Ball BJ, Hsu M, Devlin SM, Arcila M, Roshal M, Zhang Y, Famulare CA, Goldberg AD, Cai SF, Dunbar A, Epstein-Peterson Z, Menghrajani KN, Glass JL, Taylor J, Viny AD, Giralt SS, Gyurkocza B, Shaffer BC, Tamari R, Levine RL, Tallman MS, Stein EM. Ball BJ, et al. Among authors: goldberg ad. Am J Hematol. 2021 May 1;96(5):E171-E175. doi: 10.1002/ajh.26146. Epub 2021 Mar 24. Am J Hematol. 2021. PMID: 33650111 Free PMC article. No abstract available.
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.
Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD. Stahl M, et al. Among authors: goldberg ad. Blood Adv. 2021 Mar 9;5(5):1552-1564. doi: 10.1182/bloodadvances.2020003734. Blood Adv. 2021. PMID: 33687434 Free PMC article.
131 results